Table 2.
Selected comorbid conditions
| Variable | Number (%) of participants | ||
|---|---|---|---|
| Total population | Mild (n = 547) | Moderate (n = 520) | Severe (n = 400) |
| ≥1 atopic comorbidity | 322 (58.9)* | 388 (74.6)† | 322 (80.5) |
| Asthma | 111 (20.3)* | 165 (31.7)* | 174 (43.5) |
| Food allergies | 55 (10.1)* | 98 (18.8)† | 101 (25.3) |
| Seasonal allergies | 179 (32.7)* | 219 (42.1) | 176 (44.0) |
| Atopic keratoconjunctivitis | 2 (0.4)* | 5 (1.0)† | 12 (3.0) |
| ≥1 non‐atopic comorbidity | 228 (41.7)* | 243 (46.7)† | 217 (54.3) |
| Emotional or mental conditions | 92 (16.8)* | 107 (20.6)* | 125 (31.3) |
| Cardiac/vascular conditions | 46 (8.4) | 56 (10.8) | 48 (12.0) |
| Musculoskeletal/integument conditions | 34 (6.2) | 37 (7.1) | 35 (8.8) |
| Endocrine/metabolic conditions | 41 (7.5) | 52 (10.0) | 44 (11.0) |
| Urology/renal condition | 10 (1.8) | 14 (2.7) | 9 (2.3) |
| Variable | Number (%) of participants | |||
|---|---|---|---|---|
| Subpopulations |
Cyclo (n = 62) |
Severe excluding Cyclo (n = 360) |
IMM (n = 104) |
Severe excluding IMM (n = 340) |
| ≥1 atopic comorbidity | 53 (85.5) | 289 (80.3) | 85 (81.7) | 272 (80.0) |
| Asthma | 38 (61.3)ߥ | 149 (41.4) | 62 (59.6)§ | 137 (40.3) |
| Food allergies | 20 (32.3) | 86 (23.9) | 31 (29.8) | 81 (23.8) |
| Seasonal allergies | 32 (51.6) | 156 (43.3) | 45 (43.3) | 151 (44.4) |
| Atopic keratoconjunctivitis | 2 (3.2) | 10 (2.8) | 4 (3.8) | 8 (2.4) |
| ≥1 non‐atopic comorbidity | 48 (77.4)§ | 186 (51.7) | 79 (76.0)§ | 171 (50.3) |
| Emotional or mental conditions | 29 (46.8)ߥ | 102 (28.3) | 45 (43.3)ߥ | 94 (27.6) |
| Cardiac/vascular conditions | 14 (22.6)ߥ | 37 (10.3) | 24 (23.1)§ | 32 (9.4) |
| Musculoskeletal/integument conditions | 6 (9.7) | 31 (8.6) | 14 (13.5) | 28 (8.2) |
| Endocrine/metabolic conditions | 7 (11.3) | 38 (10.6) | 13 (12.5) | 35 (10.3) |
| Urology/renal condition | 5 (8.1)§ | 5 (1.4) | 6 (5.8)ߥ | 5 (1.5) |
*P < 0.001 and †P ≤ 0.05 vs. IGA severe; ߥP ≤ 0.05 and §P ≤ 0.001 for Cyclo or IMM groups vs. severe groups excluding Cyclo/IMM participants, respectively.
Cyclo, participants with inadequate efficacy for or contraindications or intolerance to cyclosporine; IGA, Investigator's Global Assessment; IMM, participants with inadequate efficacy for or contraindications or intolerance to any systemic immunomodulatory agent (including Cyclo participants).